Theseus goes with Tang; Oncternal trial patient dies; LianBio sells drug rights to J&J
2023-12-27
临床2期并购临床3期
Plus, news on the Immunome-Atreca asset deal, Cyclo Therapeutics’ reverse merger, Nestlé buying CDX-7108 from Codexis, Oncternal, Visiox and more.
So long, Applied Molecular Transport:
The stock symbol $AMTI officially became history as Cyclo Therapeutics
completed
its reverse merger and took Applied Molecular Transport’s spot on the Nasdaq under the ticker
$CYTH
. Applied Molecular Transport began hunting for strategic alternatives in
late March
after it halted all R&D activities and laid off the bulk of its staff in the wake of a Phase II flop in ulcerative colitis. The deal with Cyclo was
announced
in September. The company will now focus on a Phase III study of its reformulated drug for Niemann-Pick Disease Type C1.
— Amber Tong
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。